J
Jörg Thomalla
Researcher at Praxis
Publications - 43
Citations - 1206
Jörg Thomalla is an academic researcher from Praxis. The author has contributed to research in topics: Breast cancer & Internal medicine. The author has an hindex of 12, co-authored 36 publications receiving 743 citations.
Papers
More filters
Journal ArticleDOI
A randomised phase II study investigating durvalumab in addition to an anthracycline taxane-based neoadjuvant therapy in early triple-negative breast cancer: clinical results and biomarker analysis of GeparNuevo study
S. Loibl,Michael Untch,Nicole Burchardi,J Huober,Bruno Valentin Sinn,J-U Blohmer,EM Grischke,Jenny Furlanetto,Hans Tesch,Claus Hanusch,Knut Engels,Mahdi Rezai,C. Jackisch,Wolfgang D. Schmitt,G. von Minckwitz,Jörg Thomalla,S Kümmel,Beate Rautenberg,PA Fasching,Karsten Weber,K Rhiem,Carsten Denkert,Andreas Schneeweiss +22 more
TL;DR: The results suggest that the addition of durvalumab to anthracycline/taxane based NACT increases pCR rate particularly in patients treated with durvalUMab alone prior to start of chemotherapy.
Journal ArticleDOI
Assessment of imatinib as first-line treatment of chronic myeloid leukemia: 10-year survival results of the randomized CML study IV and impact of non-CML determinants
Rüdiger Hehlmann,Michael Lauseker,Susanne Saußele,Markus Pfirrmann,Stefan W. Krause,Kolb Hj,Andreas Neubauer,D.K. Hossfeld,Christoph Nerl,Alois Gratwohl,Gabriela M. Baerlocher,Dominik Heim,Tim H. Brümmendorf,Alice Fabarius,Claudia Haferlach,Brigitte Schlegelberger,Martin C. Müller,Sabine Jeromin,Ulrike Proetel,Katharina Kohlbrenner,A. Voskanyan,Sebastien Rinaldetti,Wolfgang Seifarth,Birgit Spieß,Leopold Balleisen,M. C. Goebeler,Mathias Hänel,A. D. Ho,Jolanta Dengler,C. Falge,Lothar Kanz,Stephan Kremers,Andreas Burchert,Michael Kneba,Frank Stegelmann,C. A. Köhne,Hans-Walter Lindemann,Cornelius F. Waller,Michael Pfreundschuh,Karsten Spiekermann,Wolfgang E. Berdel,Lutz P. Müller,Matthias Edinger,Jiří Mayer,Dietrich W. Beelen,Martin Bentz,Hartmut Link,Bernd Hertenstein,R. Fuchs,Martin Wernli,F. Schlegel,Rudolf Schlag,M. de Wit,Lorenz Trümper,Holger Hebart,Markus Hahn,Jörg Thomalla,Christoph Scheid,Philippe Schafhausen,Walter Verbeek,Michael J. Eckart,Winfried Gassmann,Antonio Pezzutto,Michael Schenk,Peter Brossart,Thomas Geer,S. Bildat,E. Schäfer,Andreas Hochhaus,Joerg Hasford +69 more
TL;DR: In a multivariate analysis, risk group, major-route chromosomal aberrations, comorbidities, smoking and treatment center (academic vs other) influenced survival significantly, but not any form of treatment optimization.
Journal ArticleDOI
Durvalumab improves long-term outcome in TNBC: results from the phase II randomized GeparNUEVO study investigating neodjuvant durvalumab in addition to an anthracycline/taxane based neoadjuvant chemotherapy in early triple-negative breast cancer (TNBC).
Sibylle Loibl,Andreas Schneeweiss,Jens Huober,Michael Braun,Julia Rey,Jens Uwe Blohmer,Jenny Furlanetto,Dirk Michael Zahm,Claus Hanusch,Jörg Thomalla,Christian Jackisch,Peter Staib,Theresa Link,Kerstin Rhiem,Christine Solbach,Peter A. Fasching,Nicole Burchardi,Carsten Denkert,Michael Untch +18 more
TL;DR: The GeparNuevo trial investigated the addition of durvalumab, an anti-PD-L1 checkpoint inhibitor (CPI), to standard neoadjuvant chemotherapy (NACT) in patients with early TNBC.
Journal ArticleDOI
High anti-lymphoma activity of bendamustine/mitoxantrone/rituximab in rituximab pretreated relapsed or refractory indolent lymphomas and mantle cell lymphomas. A multicenter phase II study of the German Low Grade Lymphoma Study Group (GLSG).
Rudolf Weide,Georg Hess,Hubert Köppler,Jochen Heymanns,Jörg Thomalla,Ali Aldaoud,Christoph Losem,Stefan Schmitz,Ursula Haak,Christoph Huber,Michael Unterhalt,Wolfgang Hiddemann,Martin Dreyling +12 more
TL;DR: BMR is a very effective new outpatient immuno-chemotherapy with low toxicity for patients with relapsed/refractory FL, MCL and other indolent lymphomas, and unexpected hospitalisations were necessary after 4% of BMR-application only.
Journal ArticleDOI
Intense dose-dense epirubicin, paclitaxel, cyclophosphamide versus weekly paclitaxel, liposomal doxorubicin (plus carboplatin in triple-negative breast cancer) for neoadjuvant treatment of high-risk early breast cancer (GeparOcto-GBG 84): A randomised phase III trial.
Andreas Schneeweiss,Volker Möbus,Hans Tesch,Claus Hanusch,Carsten Denkert,Kristina Lübbe,Jens Huober,Peter Klare,Sherko Kümmel,Michael Untch,Karin Kast,Christian Jackisch,Jörg Thomalla,Barbara Ingold-Heppner,Jens-Uwe Blohmer,Mahdi Rezai,Matthias Frank,Knut Engels,Kerstin Rhiem,Peter A. Fasching,Valentina Nekljudova,Gunter von Minckwitz,Sibylle Loibl +22 more
TL;DR: In high-risk early BC there is no difference in pCR rates following neoadjuvant treatment with iddEPC or weekly PM(Cb), respectively, and idd EPC is one of the effective dose-dense regimens feasible in daily practice.